The Remifentanil Hydrochloride Injec, cataloged under National Stock Number 6505-01-442-0350, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxo Wellcome Inc. Government technical data includes 1 specification, cited from the U.S. Government catalog. The record lists 3 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 2 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6505-01-442-0350 |
| Primary Part Number | NDC00173-0484-00 |
| Item Name | Remifentanil Hydrochloride Injec |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxo Wellcome Inc |
| Status | ACTIVE |
| General Characteristics Item Description | LYOPHILIZED; REQUIRES WATER FOR RECONSTITUTION; 2 MG; VIAL; 5 MLS AFTER RECONSTITUTION; 10 VIALS PER PKG SCHEDULE II DRUGS |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| NDC00074-4504-05 | Abbott Laboratories, Inc. Dba Ross Products Division Div Ross Products (USA) |
| NDC00074-4504-05 | Abbott Laboratories Diagnostics Div (USA) |
| NDC00173-0484-00 PRIMARY | Glaxo Wellcome Inc (USA) |
| Reference | Meaning |
|---|---|
| 97-0032 | 5/1 Secondary reference U.S. Government activity |
| ULTIVA | 5/1 Secondary reference Glaxo Wellcome Inc |
NSN 6505-01-442-0350 is a Remifentanil Hydrochloride Injec, manufactured by Glaxo Wellcome Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-442-0350 has 3 manufacturer part numbers on file: NDC00074-4504-05 (Abbott Laboratories, Inc. Dba Ross Products Division Div Ross Products), NDC00074-4504-05 (Abbott Laboratories Diagnostics Div), NDC00173-0484-00 (Glaxo Wellcome Inc).
Key specifications for NDC00173-0484-00: General Characteristics Item Description: LYOPHILIZED; REQUIRES WATER FOR RECONSTITUTION; 2 MG; VIAL; 5 MLS AFTER RECONSTITUTION; 10 VIALS PER PKG SCHEDULE II DRUGS; Part Name Assigned by Controlling Agency: REMIFENTANIL HYDROCHLORIDE INJECTION 2MG 5ML VIAL 10S PG. 1 specification is documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.